Chuck Shih leads Pew’s drug spending research initiative, which identifies policy options to help manage drug costs and ensure that patients have access to lifesaving treatments.
Prior to joining Pew, he held a fellowship in health policy at the National Pharmaceutical Council and George Washington University School of Public Health and Health Services.
Shih previously worked at the Centers for Medicare & Medicaid Services, where he was an analyst in the Coverage and Analysis Group and developed Medicare coverage policies for medical devices, pharmaceuticals, and procedures. He also served as a fellow at the Agency for Healthcare Research and Quality, where he advanced and implemented the Healthcare Horizon Scanning System, and served as a project officer for the creation of comparative effectiveness evidence reports and systematic reviews in the Effective Health Care Program.
Shih received a doctorate and master of health science degree from Johns Hopkins Bloomberg School of Public Health and a bachelor’s degree from Johns Hopkins University.
Recent WorkView All
Drug spending is a complex issue that involves a range of products, policies, and stakeholders across the health care system. Understanding the many factors that affect drug spending is critical to grasping how pharmaceuticals are priced and purchased. These definitions provide a frame of reference when examining the drug spending debate. Read More
Biological products, or biologics, are drugs made up of proteins or other materials derived from living cells through a complex manufacturing process. They are used to treat a wide range of health conditions, including cancer, rheumatoid arthritis, and multiple sclerosis, and are some of the most expensive drugs on the market, measured by both unit price and net contribution to spending. In 2015,... Read More
The Pew Charitable Trusts sent a letter Aug. 11 to the Centers for Medicare & Medicaid Services summarizing possible unintended consequences of a proposal to reduce Medicare Part B payments to hospitals participating in the 340B Drug Discount Program, such as hospitals choosing to forgo discounted medicines in favor of the list price. Read More